Evidence map›Paper›PMID 41971397›Full record

ArticleNew microbes and new infections2026

Increase in imported mupirocin-resistant

Maria Cristina Moreno-Del Castillo, Daniel Humme, Rasmus Leistner, Renate Krüger, Miriam Stegemann, Leif Hanitsch, Franziska Layer-Nicolaou, Andreas Knaust, Josef G Sägmüller, Angela Stein and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Maria Cristina Moreno-Del CastilloCharité - Universitätsmedizin Berlin, Charité Center for Global Health, Institute of International Health, Berlin, Germany.
Daniel HummeCharité - Universitätsmedizin Berlin, Interdisciplinary Workgroup on PVL-positive S. aureus, Berlin, Germany.
Rasmus LeistnerCharité - Universitätsmedizin Berlin, Interdisciplinary Workgroup on PVL-positive S. aureus, Berlin, Germany.
Renate KrügerCharité - Universitätsmedizin Berlin, Interdisciplinary Workgroup on PVL-positive S. aureus, Berlin, Germany.
Miriam StegemannCharité - Universitätsmedizin Berlin, Interdisciplinary Workgroup on PVL-positive S. aureus, Berlin, Germany.
Leif HanitschCharité - Universitätsmedizin Berlin, Interdisciplinary Workgroup on PVL-positive S. aureus, Berlin, Germany.
Franziska Layer-NicolaouCharité - Universitätsmedizin Berlin, Interdisciplinary Workgroup on PVL-positive S. aureus, Berlin, Germany.
Andreas KnaustLabor Berlin Charité Vivantes GmbH, Berlin, Germany.
Josef G SägmüllerLabor Berlin Charité Vivantes GmbH, Berlin, Germany.
Angela SteinLabor Berlin Charité Vivantes GmbH, Berlin, Germany.
Paul PitzingerCharité - Universitätsmedizin Berlin, Charité Center for Global Health, Institute of International Health, Berlin, Germany.
Alice HuckoCharité - Universitätsmedizin Berlin, Charité Center for Global Health, Institute of International Health, Berlin, Germany.
Jessica L RohmannBerlin Institute of Health at Charité- Universitätsmedizin Berlin, QUEST Center for Responsible Research, Berlin, Germany.
Frank P MockenhauptCharité - Universitätsmedizin Berlin, Charité Center for Global Health, Institute of International Health, Berlin, Germany.
Beate KampmannCharité - Universitätsmedizin Berlin, Charité Center for Global Health, Institute of International Health, Berlin, Germany.
Dennis NurjadiUniversity of Lübeck and University Hospital Schleswig-Holstein, Lübeck, Institute of Medical Microbiology, Lübeck, Germany.
Philipp ZangerUniversity Hospitals, Heidelberg, Heidelberg Institute of Global Health (HIGH), Heidelberg, Germany.
Andreas K LindnerCharité - Universitätsmedizin Berlin, Charité Center for Global Health, Institute of International Health, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mupirocin resistance in Methods: We calculated annual percentages of Mup-RSA and MRSA among Results: From January 1, 2018, to June 30, 2025, Mup-RSA was detected in 3.1% (24/782) of patients with Conclusion: Mup-RSA proportions are low overall, but have increased substantially in Tropical Medicine, with modest increases in Dermatology. Clinicians should be aware of both the emergence of Mup-RSA and the availability of alternative topical agents for decolonisation, particularly in contexts where

Indexed as

Antimicrobial resistanceDecolonisationInfection controlMethicillin-resistant Staphylococcus aureusMRSAMupirocin resistancePanton-valentine leucocidinPVLSkin and soft tissue infectionsStaphylococcus aureus

Identifiers

PMID41971397
PMCPMC13068841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.